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Abstract
Despite decades of published data regarding the application of autologous and allogeneic stem cell
transplant in patients with follicular lymphoma, there remain no uniform indications for its use in
this disease. Autologous transplant has been shown to lead to longer progression-free survival times
in randomized trials when compared with postremission interferon-based chemo-immunotherapy.
However, the development of rituximab and its use in frontline, salvage, and maintenance therapy
complicates the decision to pursue autologous transplant, a modality developed prior to the advent
of anti-CD20 monoclonal antibodies. Allogeneic transplant offers the advantages of lymphoma-free
grafts and the immunologic graft-versus-lymphoma effect. These factors may confer the possibility
of long-term remission, though historically they have been accompanied by high rates of upfront
morbidity and mortality, especially in heavily pretreated patients with a poor performance status or
chemotherapy-refractory disease. Advances in patient selection, human leukocyte antigen (HLA)
matching, conditioning regimens, and supportive care have reduced transplant-related mortality and
the incidence of graft-versus-host disease.
Recently published data focus on the incorporation of rituximab and radioimmunoconjugates prior
to, during, and following autologous transplant. Furthermore, reduced-intensity allogeneic stem cell
transplantation has increasingly been used for relapsed follicular lymphoma patients with
comorbidities or advanced age. Several recent reports suggest that reduced-intensity regimens may
provide a high likelihood of long-term disease-free survival for patients up to 70 years of age with
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a good performance status, chemotherapy-sensitive disease, and HLA-matched sibling donors. Such
patients with relapsed disease should be referred to a transplant center that can enroll them in one of
the forthcoming clinical trials that aim to confirm these outcomes.
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INTRODUCTION
Follicular lymphoma (FL) has historically been considered incurable in its advanced stages.
Typically, initial chemosensitivity is followed by progressively shorter remissions, poorer
response rates, and frequent transformation into aggressive lymphoma [1]. In past decades,
advances in chemotherapy and radiation had not impacted the natural history of the disease,
but data now suggest that recent advances have improved survival [2–4]. Hematopoietic stem
cell transplant (HSCT) was first used for FL in the 1980s [5]. Although improvements in patient
selection, conditioning regimens, and supportive care have resulted in less morbidity and
mortality [6], and superior outcomes are achieved when transplant is applied in FL prior to
histologic transformation [7], there are no uniform guidelines for the incorporation of transplant
into the management of FL. Furthermore, the advent of chemoimmunotherapy and
radioimmunotherapy has changed the therapeutic landscape, making older transplant data less
applicable to today’s patients.
Rituximab (Rituxan®; IDEC Pharmaceuticals, San Diego, and Genentech, Inc, San Francisco,
CA) has improved response rates and time to progression in patients with advanced FL, without
significant increases in toxicity [8]. Thus, for rituximab-naïve relapsed patients, the use of this
anti-CD20 monoclonal antibody either alone or with chemotherapy is an attractive option. Even
for heavily pretreated patients, the anti-CD20 radioimmunoconjugates iodine-131
tositumomab (Bexxar®; Corixa Corporation, South San Francisco, CA and GlaxoSmithKline,
Philadelphia) and yttrium-90 ibritumomab tiuxetan (Zevalin®; Spectrum Pharmaceuticals,
Inc., Irvine, CA) have induced complete and durable responses [9,10]. With these expanding
options, the optimal time and indication for transplant remains unclear despite the potential for
long-term remission and cure with these approaches.
The menu of options available to the transplant specialist is also complex. In prior decades,
transplant-related mortality (TRM) rates of up to 40% [11] made myeloablative allogeneic
HSCT practicable only for the youngest, fittest patients with human leukocyte antigen (HLA)-
matched donors. Subsequent advances in HLA matching, supportive care, and prevention and
treatment of graft-versus-host disease (GVHD) have lowered TRM rates considerably [6,12,
13]. Autologous transplant has long been available for patients who are not candidates for
allografts, though the high rate of bone marrow involvement in advanced FL makes stem cell
product contamination a concern. Ex vivo and in vivo stem cell purging and the wide array of
conditioning regimens complicate the approach to autologous transplant. Long-term follow-
up of autologous HSCT studies has also demonstrated rates of second hematologic
malignancies and solid tumors in the range of 3%–12.4% [14–16] and 1.6%–8.3% [17–20],
respectively. Mortality from these second malignancies partially negates the lower short-term
TRM rate of this approach.
These findings complicate the decision to pursue any transplant, even more so the choice
between autologous and allogeneic HSCT. Other variables include donor selection, intensity
Foster et al. Page 2













of the conditioning regimen, stem cell source, and GVHD prophylaxis. This review aims to
clarify recently published data on the application of HSCT in advanced FL.
AUTOLOGOUS TRANSPLANT
It has been nearly three decades since the first published series of patients who received
autologous bone marrow transplant for FL [5]. In the 1990s, a nonrandomized series reported
8-year disease-free survival rates of up to 42% [21]. More recently, the European Blood and
Marrow Transplantation (EBMT) group registry reported long-term outcomes of 693 FL
patients [22]. With a median follow-up of 10.3 years, the 10-year progression-free survival
(PFS) rate was 31% and the 10-year overall survival (OS) rate was 52%. Nine percent
developed second malignancies at a median of 7 years post-transplant.
Mature follow-up of patients (n = 121) in second or subsequent remission conditioned with
cyclophosphamide plus total body irradiation (TBI) was also reported recently in a two-
institution series [16]. With a median follow-up of 13.5 years, the 10-year PFS rate was 48%
and the 10-year OS rate was 54%. Though the PFS Kaplan-Meier curve achieved a plateau
beyond 8 years, the curve for OS did not, resulting, in part, from the 12.4% of patients
succumbing to treatment-related myelodysplastic syndrome (MDS) or acute myelogenous
leukemia (AML).
In attempts to solve the problem of product contamination by lymphoma, ex vivo purging of
autologous stem cell products using combinations of anti B-cell antigen monoclonal antibodies
and complement have been employed, with encouraging results [23]. In a nonrandomized case
series, patients who received purged stem cell infusions free from minimal residual disease by
polymerase chain reaction (PCR) had a higher 8-year freedom-from-relapse rate (83%,
compared with 19% for PCR+ patients; p = .0001) [21].
More recently, rituximab-containing mobilization regimens have been employed as in vivo
purging strategies [24,25]. Such approaches have yielded stem cell products apparently free
from residual lymphoma, and encouraging post-transplant outcomes have been attributed to
rituximab use in patients previously naïve to immunotherapy. An Italian group compared high-
dose sequential (HDS) therapy with or without rituximab incorporation during mobilization
[26]. When compared with historical controls treated with HDS without rituximab, those
treated with HDS plus rituximab had a superior 5-year projected OS rate (82% versus 68%;
p = .011) and event-free survival (EFS) rate (66% versus 46%; p = .001). Others have compared
such in vivo purging strategies with ex vivo CD34+ cell–enrichment techniques [27]. Both
approaches yielded B cell–free grafts but were associated with delayed hematologic recovery
in CD34+ cell–selected patients and delayed immunoglobulin reconstitution in rituximab-
purged patients. Although infectious complications did not appear frequent in this analysis,
other studies have shown a higher risk for serious infections with thoroughly purged products
[28,29].
In an attempt to definitively assess the benefit of ex vivo purging, the Chemotherapy Unpurged
or Purged (CUP) trial [30] randomized 89 patients with chemotherapy-sensitive, relapsed FL
to three cycles of chemotherapy or high-dose therapy (HDT) with either unpurged or
immunomagnetically purged autologous stem cells. That trial suffered slow accrual and was
discontinued at a sample size that only allowed comparison of chemotherapy with transplant.
Despite the failure of the CUP trial to address ex vivo purging, it remains the only randomized
trial comparing chemotherapy with HDT in relapsed FL. At a median follow-up of 69 months,
the hazard ratio (HR) for PFS was 0.30 (p = .0009) in favor of HDT. Furthermore, the HR for
OS also favored HDT over chemotherapy (HR, 0.40; p = .026).
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Autologous HSCT for FL in first remission was studied in three European multicenter,
randomized trials in the prerituximab era. These clinical trials, conducted by the German Low-
Grade Lymphoma Study Group (GLSG) [31] and the French cooperative groups Groupe Ouest
Est d’Etude des Leucémies et Autres Maladies du Sang (GOELAMS) [32] and Groupe d’Etude
des Lymphomes de l’Adulte (GELA) [33], enrolled untreated patients aged <59–61 with
symptomatic, bulky, or progressive disease. Patients received cyclophosphamide, doxorubicin,
vincristine, and prednisone (CHOP)-like induction regimens and were randomized to either 1
year of interferon-based maintenance therapy or cyclophosphamide plus TBI-based HDT with
autologous HSCT. The trials generally suggested an EFS difference in favor of autologous
transplant (Table 1), although the largest of the three trials, the GELA-sponsored Groupe
d’Etude des Lymphomes Folliculaires (GELF)-94 study, failed to reach statistical significance
with regard to disease-free survival. With the longest randomized follow-up data published to
date (9 years), a recent update of the GOELAMS trial showed longer disease-free survival in
the autologous HSCT group, along with a 16% incidence of late second cancers in the transplant
group at 10 years that resulted in a similar OS rate between groups [32].
Although the randomized trials consistently suggested longer disease-free survival times,
autologous SCT for FL has not achieved widespread application for three reasons. First, none
of the trials of autologous SCT in patients in first remission demonstrated an OS benefit. It is
thus uncertain whether autologous transplant merely delays inevitable relapse or changes the
ultimate course of disease. Second, the early benefit of a disease-free interval is partially offset
by the incidence of therapy-related MDS (tMDS) and secondary AML (sAML), previously
estimated to be between 4.3% [34] and 12.3% [35]. The GLSG trial estimated the 5-year risk
for tMDS or sAML to be 3.5% in the transplant group and 0% in the chemotherapy plus
interferon group (p = .0248) [15]. Because of the high mortality from sAML and tMDS, even
low rates of these complications may off-set early benefits of autologous transplant. Second
solid and hematologic malignancies occurred at a particularly high rate in the transplant arm
of the GOELAMS trial (16%), especially in patients whose stem cell product underwent
positive selection for CD34+ cells (33%). The authors postulate that such purging techniques
remove immunocompetent cells from the bone marrow that later participate in antitumor
activity [32]. Finally, the publication of most randomized data for autologous transplant
coincided with advances in the use of rituximab in frontline, salvage, and maintenance therapy
for FL [8,36]. The ensuing widespread use of rituximab has supplanted interferon-based
chemoimmunotherapy and made the comparator groups in these randomized trials less
germane to modern patients.
AUTOLOGOUS TRANSPLANT IN PATIENTS PREVIOUSLY TREATED WITH
RITUXIMAB
Initially, single-center retrospective series suggested that rituximab therapy prior to autologous
SCT may not benefit patients with relapsed FL. When 56 subsequently transplanted low-grade
lymphoma patients treated initially with rituximab-containing therapy were compared with 55
rituximab-naïve patients at Washington University, no differences in disease-free survival or
OS emerged [37]. A similar retrospective analysis of rituximab-pretreated versus rituximab-
naïve FL patients transplanted at the Cleveland Clinic showed no difference in disease-free
survival between the groups, although the median OS was not reached [38]. Cox multivariable
models suggested trends for shorter OS and DFS times in rituximab-pretreated patients, but
these trends did not reach statistical significance.
A large secondary analysis with mature follow-up was recently reported by GELA. The study
included FL patients treated in two prospective trials (GELF-94 and GELF-86) who did not
receive HDT or rituximab as part of their initial therapy [39]. Patients were combined for this
analysis because they received identical frontline chemoimmunotherapy with CVHP
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(cyclophosphamide, doxorubicin, teniposide/VP16, and prednisone) plus interferon followed
by bimonthly maintenance. The authors analyzed 254 patients age <61 who subsequently
relapsed. The 5-year EFS rate was greatest (67%) when patients received both rituximab-
containing salvage therapy and autologous SCT, and lowest (19%) when patients received
neither rituximab nor HSCT. Rituximab resulted in both a greater 5-year EFS rate after relapse
(patients not transplanted, 39% with rituximab versus 19% without, p = .0002; patients
transplanted, 67% versus 46%, p = .0532) and a greater 5-year OS rate after relapse regardless
of transplant status (patients not transplanted, 70% with rituximab versus 33% without, p < .
0001; transplanted patients, 93% versus 63%, p = .0071). Although demonstrating a trend
favoring rituximab plus SCT, the benefit of SCT in patients who received rituximab-based
salvage regimens did not reach statistical significance (EFS rate for SCT versus non-SCT
patients, 67% versus 39%, p = .16; OS for SCT versus non-SCT patients, 93% versus 70%,
p = .13). Because the choice of salvage therapy and SCT was at the discretion of physicians,
selection bias prevents definitive conclusions about the superiority of the various approaches.
Two recent abstracts from Germany also address the issue of autologous transplant in FL
patients who received first-line rituximab plus CHOP (R-CHOP). A retrospective study
combined patients enrolled in the CHOP-containing arms of two GLSG trials, ’96 (CHOP
versus mitoxantrone, chlorambucil, and prednisone followed by randomization to interferon
maintenance versus autologous SCT) and ’00 (CHOP versus R-CHOP followed in responding
patients aged <60 years by randomization to interferon maintenance versus autologous SCT).
Patients who received R-CHOP followed by autologous SCT in first complete remission (5-
year PFS rate, 79%) fared better than those receiving CHOP with interferon maintenance
(27%), CHOP with autologous SCT (66%), or R-CHOP with interferon maintenance (67%)
[40]. However, in a comparison of transplanted patients in the ’00 trial, no significant benefit
emerged for frontline R-CHOP (5-year PFS, 78%) over CHOP (66%; p = .43). An insufficient
number of events at a median follow-up of 58 months of these groups makes further follow-
up necessary [41].
More recently, the Italian cooperative group published data at a median follow-up of 51 months
from the Gruppo Italiano Trapianto di Midollo Osseo/Intergruppo Italiano Linfomi (IIL)
randomized trial of 136 patients with high-risk, untreated stage III or IV FL [42]. High-risk
disease status was defined as an age-adjusted International Prognostic Index (IPI) score [43]
≥2 or an IIL score [44] ≥3. Patients were randomized to either six courses of CHOP-21 followed
by four doses of rituximab or the HDS regimen (sequential doxorubicin, vincristine, and
prednisone followed by 2 g/m2 etoposide and subsequently 7 g/m2 cyclophosphamide for
mobilization) with rituximab incorporated both prior to and following cyclophosphamide as
an in vivo purging strategy (R-HDS regimen) prior to autograft conditioned with mitoxantrone
and melphalan. Similar to the randomized trials conducted prior to the widespread use of
rituximab, the EFS rate was superior in the transplanted arm (4-year projected EFS rate, 61%
versus 28%; p < .001) without any impact on the OS rate (CHOP-R, 80%; R-HDS, 81%; p = .
96). Partly responsible for the similar OS data was a trend toward higher a 4-year cumulative
incidence of second hematologic cancer (AML/MDS) that was seen in the R-HDS group (6.6%,
versus 1.7% with CHOP-R; p = .111). However, another explanation for the similar survival
rates in the two groups remains the fact that patients with relapsed or refractory lymphoma
after CHOP-R had 3-year EFS and OS rates of 64% and 73%, respectively, and 3-year EFS
and OS rates of 68% and 81%, respectively, if salvaged with R-HDS. Furthermore, using bone
marrow PCR for molecular monitoring, the authors found that patients in molecular remission
had similar EFS rates regardless of treatment arm, and patients not in molecular remission
likewise had similar outcomes. Such patterns in the data suggest that upfront autologous
transplant may result in more durable remissions than conventional chemoimmunotherapy but
not alter the ultimate course of disease.
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COMPARISONS BETWEEN AUTOLOGOUS AND ALLOGENEIC SCT
The theoretical advantages of allogeneic transplant lie in immunologic graft-versus-tumor
effects and the use of cell products devoid of tumor cells and prior chemotherapy-induced DNA
damage. These advantages should lead to lower rates of relapse and second hematologic
malignancies. Clinical evidence of a graft-versus-lymphoma (GVLy) effect is suggested by a
late plateau in the rates of relapse seen in allogeneic HSCT recipients, whereas patients
receiving autologous transplants relapse continuously [45]. Evidence in support of the GVLy
effect in FL has been demonstrated by molecular responses after tapered immunosuppression
and donor lymphocyte infusion in patients who relapse after allograft [46,47].
A retrospective analysis of non-Hodgkin’s lymphoma (NHL) patients in the International Bone
Marrow Transplant Registry and the EBMT registry called the GVLy phenomenon into
question by demonstrating equally low rates of relapse in syngeneic and full-intensity
allogeneic transplant recipients [48]. Importantly, chemosensitivity was inversely related to
relapse on multivariate analysis, and fewer allograft recipients demonstrated chemosensitivity
prior to transplant than did syngeneic graft recipients. This discrepancy, along with the
retrospective nature of the study, suggests that unmeasured differences between patient groups
may have existed. The inclusion of diverse NHL histologies also precludes specific conclusions
regarding FL.
The only prospective comparison between autologous and allogeneic HSCT for relapsed FL
closed early as a result of poor accrual [49]. The largest published retrospective study included
904 patients who underwent autologous or HLA-matched, sibling donor allogeneic HSCT at
member institutions of two registries between 1990 and 1999 [6]. At baseline, the group
receiving allogeneic transplants was younger and more likely to have a poor performance
status, an elevated lactate dehydrogenase level, bone marrow involvement, and chemotherapy-
resistant disease. The 5-year estimates of disease-free survival (45% versus 39% versus 31%)
and OS (51% versus 62% versus 55%) were similar among the allogeneic, purged autologous,
and unpurged autologous groups, respectively. Although relapse rates in allogeneic HSCT
recipients demonstrated a plateau at 21% between 3 and 5 years post-transplant, relapses
continued in autologous HSCT patients beyond 3 years. This difference in relapse rates was
offset in the OS analysis by a higher TRM rate in the allogeneic group (24% at 1 year versus
4%–8% at 1 year for autologous SCT recipients).
Similar patterns of lower relapse rates but a higher nonrelapse mortality (NRM) rate with
allogeneic SCT were observed in recent retrospective studies of allogeneic versus autologous
SCT in FL [50,51]. The EBMT compared registry patients receiving autologous SCT for
relapsed FL (n = 1,394) with those receiving reduced-intensity allogeneic SCT (n = 110)
[50]. The risk for NRM was higher in allograft patients (risk ratio [RR], 3.5; p < .001), but the
risk for relapse was greater in autografted patients (RR, 2.8; p < .001).
A two-center British study reported on 126 patients who underwent either unpurged autologous
transplant with BCNU, etoposide, cytarabine, and melphalan (BEAM) or allogeneic HSCT
after conditioning with BEAM plus alemtuzumab. Again, significant differences were seen in
terms of the TRM rate (20% for allogeneic SCT, 2% for autologous SCT; p = .001) and relapse
rate at 3 years (20% in the allogeneic group, 43% in the autologous group; p = .01). However,
the 3-year disease-free survival rates (allogeneic, 58%; autologous, 56%; p = .9) and OS rates
(allogeneic, 69%; autologous, 67%; p = .99) were indistinguishable. In patients followed
beyond 3 years, a trend is emerging for a plateau in terms of both OS and disease-free survival
in allogeneic HSCT recipients, but autologous SCT patients suffer both late relapses and second
malignancies. Efforts to refine patient selection, supportive care, and treatment of GVHD may
eventually result in a survival benefit for allogeneic over autologous HSCT. At the same time,
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the use of reduced-intensity allografts following failed autotransplants has resulted in
encouraging results that suggest that such an approach may lead to effective salvage of patients
initially treated with an autologous transplant [52]. Nevertheless, without prospective,
randomized comparisons between autologous and allogeneic transplants, the decision to pursue
autograft or allograft for an individual patient must involve a balanced discussion of the risks
of early mortality and late second malignancies, along with an acknowledgment of the
limitations of the currently available retrospective data.
REDUCED-INTENSITY ALLOGENEIC TRANSPLANT
With the goal of making allogeneic transplant feasible for older, heavily pretreated patients,
reduced-intensity conditioning (RIC) regimens were first reported in relapsed lymphoma
patients almost 10 years ago [53]. The bulk of the experience with RIC regimens is published
in the form of single-arm case series of relapsed NHL patients (Table 2). The earliest
retrospective studies of RIC reported data from multicenter registries. The EBMT reported 188
patients from 51 centers, with only 52 low-grade lymphoma patients [54]. Follow-up was
limited (median, 283 days), and patients were treated with 17 different conditioning regimens.
Sixteen percent of patients either had chemotherapy-resistant disease or were in untreated
relapse prior to transplant. Despite a disappointing 2-year estimated TRM rate of 30.9%, the
PFS rate (54%), OS rate (65%), and incidences of both acute (24%) and extensive chronic (9%)
GVHD were considered acceptable. on multivariate analysis, age >50 years predicted TRM
(RR, 2.02; 95% confidence interval [CI], 1.03– 4.0; p = .041), and the presence of
chemosensitivity prior to transplant predicted favorable PFS and OS times (RR, 2.3; 95% CI,
1.4 –3.7; p = .007 and RR, 2.4; 95% CI, 1.4–4.2; p = .002, respectively).
Retrospective surveys conducted in Japan [55] and France [13] also evaluated patients, with
varied NHL histology at multiple centers, who underwent heterogeneous conditioning
regimens. Follow-up was limited in the Japanese study (median, 23.9 months), and only 3-year
survival estimates are reported for the indolent lymphoma subgroup, with a PFS rate of 77%
and an OS rate of 79%. Multivariate analysis identified that indolent histology, methotrexate-
containing GVHD prophylaxis, performance status score of 0–1, and a long interval from
diagnosis to transplant had a favorable effect on PFS (all p < .05). With the longest median
follow-up (37 months) of all retrospective studies, the French series showed disappointing rates
of PFS (51%; 95% CI, 40%–64%) and OS (56%; 95% CI, 45%–69%). Furthermore, the
reported TRM rate of 40% was similar to that reported using myeloablative regimens [11]. The
reasons for poor outcomes in these heterogeneous groups is unclear, but may be related to lack
of standardized GVHD prophylaxis and a significant incidence of GVHD. Furthermore, 16.4%
of the French patients had chemotherapy-resistant lymphoma prior to transplant, a factor
previously identified to predict poor outcome [54].
Reflecting an aggressive application of RIC allogeneic SCT for FL, 37% of 54 patients
transplanted within the Seattle-based consortium had progressive disease or untreated relapse
prior to transplant [56]. Accordingly, the entire cohort, 26% of whom had transformed disease,
experienced rates of TRM (42%), PFS (38%), and OS (43%) that were generally inferior to
those reported in other retrospective series. Additionally, the frequency of matched-unrelated
donor transplants (31%) and HLA-mismatched allografts (22%) was likely responsible for the
high incidences of acute (63%) and extensive chronic (47%) GVHD.
In general, three prospective studies of RIC in FL have reported the most favorable outcomes
with regard to TRM, incidence of GVHD, and survival (Table 2). Such outcomes are likely
the result of selective inclusion criteria inherent to prospective trials. For instance, neither the
phase II MD Anderson trial incorporating rituximab into RIC [57] nor the Cancer and Leukemia
Group B (CALGB) 109901 trial [58] enrolled patients with chemotherapy-refractory disease.
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Only 2.4% of the patients in a British study of alemtuzumab added to a fludarabine–melphalan
conditioning regimen had refractory disease prior to transplant [59]. Requirements for HLA
matching were also strict in these prospective studies, with no mismatched grafts in either the
CALGB or MD Anderson studies. Unrelated donors were rare, at 0%, 4%, and 26% in the
CALGB, MD Anderson, and U.K. studies, respectively. Accordingly, rates of GVHD, TRM,
PFS, and OS were generally more favorable in those trials than in the retrospective studies.
With a median follow-up of 60 months, the MD Anderson series nearly doubles the maturity
of other reports. This considerable experience with a single rituximab, fludarabine, and
cyclophosphamide-containing regimen over 8 years has yielded impressive PFS (83%; 95%
CI, 69%–91%) and OS (85%; 95% CI, 71%–93%) rates. Furthermore, only six of the 47
patients suffered infection-related death after a regimen that targeted both cellular and humoral
immunity. These promising results deserve further investigation in a prospective, multicenter
fashion such as is currently available through the Blood and Marrow Transplant Clinical Trials
Network (BMT CTN).
COMPARISONS BETWEEN MYELOABLATIVE CONDITIONING AND RIC
The limited data comparing myeloablative conditioning with RIC allogeneic SCT in FL are
summarized in Table 3. Prior to 2008, the only published comparison of the two approaches
came from a City of Hope report that included small numbers of FL patients among patients
of varied NHL histologies [60]. Although there were no differences with regard to survival,
GVHD, or mortality, the sample was likely underpowered to show such differences.
In 2008, two similar single-institution series were published comparing fully myeloablative
allografts with RIC allografts in relapsed FL. A report from the University of Minnesota
described small numbers of indolent lymphoma patients who were treated with varied
conditioning regimens and cell products including bone marrow, peripheral blood stem cells
(PBSCs), and umbilical cord blood (UCB) [61]. With 3 years of follow-up, no differences with
regard to OS, PFS, or GVHD were detected. However, there was a significantly lower TRM
rate in the RIC group (17%, versus 43% in the myeloablative transplant recipients; p = .05).
There was no subgroup analysis for indolent lymphoma patients.
In Seattle, 41 FL patients were included in RIC and myeloablative cohorts [62]. The two groups
were treated with standardized institutional conditioning protocols. Within the low-grade
lymphoma subgroup, patients had a trend toward a lower risk for relapse with myeloablative
conditioning, but these patients had a higher risk for TRM (3.16; p = .02). When analyzed
according to the previously validated [63] HCT-specific comorbidity index (HCT-CI), which
approximates a patient’s cumulative burden of mild, moderate, and severe organ impairment,
patients without comorbidities had similar TRM and OS rates regardless of conditioning
intensity, whereas patients with high comorbidity scores fared better with RIC (HR for TRM,
0.47: p = .009; HR for OS, 0.63; p = .04).
The largest published retrospective analysis of RIC versus myeloablative conditioning
regimens for FL patients was conducted by the international registry Center for International
Bone Marrow Transplant Research [12]. The study included 120 patients who received
matched sibling allografts after myeloablative conditioning and 88 who underwent RIC
between 1997 and 2002. RIC patients were older, more likely to be in or beyond second
remission, more likely to have received prior rituximab, and more likely to receive PBSCs
rather than marrow-derived stem cells (all p < .05). As expected in a registry population,
individual conditioning regimens varied considerably. Despite the larger population studied,
no statistically significant differences in PFS, OS, or TRM emerged. There was a trend toward
a greater PFS rate in the myeloablative group (67%, versus 55%; p = .07). On multivariate
analysis, there were significantly higher rates of treatment failure and TRM, with a lower OS
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rate in patients with Karnofsky Performance Status scores <90 or chemotherapy-refractory
disease. Rates of acute GVHD were similar between the groups, though chronic GVHD was
more common in those receiving RIC, perhaps because of the more frequent use of PBSCs in
this group.
Despite the similar survival rates reported in these large cohorts, the probability of progression
3 years post-transplant was higher in RIC patients (17%, versus 8% for myeloablative patients),
a difference that persisted in a multivariate analysis (RR for progression in RIC patients, 2.97;
95% CI, 1.03– 8.55; p = .044). The differences in baseline age and disease history between
groups in this study reflect improvements in patient selection for the two approaches. There
were likely unmeasured variables such as organ dysfunction and comorbidities that led to
differences in patient selection for RIC over myeloablative regimens. Such variables could
obscure differences in outcomes that may become apparent in prospective evaluations of well-
matched patients.
A similar analysis restricted to recipients of matched unrelated donor allografts was presented
by the EBMT [52]. The 93 patients who underwent RIC transplants had a higher 3-year NRM
rate (34%, versus 46%; p < .001), PFS rate (43%, versus 35%; p = .004), and OS rate (49%,
versus 40%; p = .001) when compared with the 51 patients who received conventional
myeloablative conditioning. RIC patients were older and were more likely to have failed a prior
autograft than myeloablative patients. Taken together, these results suggest that RIC transplants
may offer equivalent or superior survival for patients aged >50 or those with significant
comorbidities, when compared with the use of fully ablative transplants in such patients.
NOVEL DIRECTIONS
Despite encouraging results, neither autologous nor allogeneic transplant has been widely
adopted in FL. Autograft tumor contamination and late development of secondary AML/MDS
after HDT remain barriers to the widespread application of these approaches, as do advances
in competing nontransplant therapies. The application of allotransplant remains limited as a
result of TRM, GVHD, and the availability of HLA-matched donors. UCB transplants have
the advantages of increasing the donor pool for patients without an HLA-compatible donor
and rapid procurement of stem cells. Despite the promise of UCB, there is limited published
experience regarding its use in adults with NHL [61,64,65].
In attempts to deliver therapeutic radiation doses without the toxicity of TBI,
radioimmunotherapy (RIT) has been employed in autologous transplant regimens for FL. The
radioimmunoconjugate yttrium-90 ibritumomab tiuxetan has been added to HDT in phase II
studies of relapsed B-cell lymphomas (with small subsets of FL patients) [66,67]. Toxicity
appears to be acceptable, with median times to engraftment of 10–12 days and low TRM rates
(0%–3%). Furthermore, a retrospective comparison suggests longer survival with yttrium-90-
based RIT HDT than with TBI-based autologous HSCT [68]. Emerging evidence also suggests
that RIT-based RIC allogeneic HSCT can be accomplished with acceptable morbidity and
TRM [69].
A chemotherapy-free regimen of high-dose 131I-tositumomab has been used with favorable
results in patients aged >60 [70], even when compared with historical controls who received
conventional HDT [71]. To date, no prospective studies have compared RIT-based autologous
transplant with conventional HDT for FL.
CONCLUSIONS
Despite much published experience in the application of SCT in FL, there remains no consensus
on the timing, patient selection, conditioning regimen, or stem cell source. The expanding menu
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of nontransplant therapies makes the risk for TRM unattractive to many patients and physicians.
Many transplant studies are retrospective analyses of patients with varied lymphoma
histologies who received diverse conditioning regimens. Comparisons between older and
newer therapeutic strategies suffer from disparate durations of follow-up. The fact that much
of the transplant data was collected in the prerituximab era also hinders comparison of
transplant and nontransplant outcomes for patients diagnosed and treated within the last 10
years. Nevertheless, for a disease that has traditionally been considered incurable in its
advanced stages, optimism about the plateau of relapse curves in allogeneic transplant studies
is appropriate.
Studies have uniformly shown inferior transplant outcomes for patents with chemotherapy-
refractory disease, poor performance status, and comorbidities [72]. These consistencies
suggest that early identification and referral of high-risk, fit patients with chemotherapy-
sensitive disease may be the optimal transplant strategy. Based on published experience with
performance status [72], the Follicular Lymphoma IPI [73], the HCT-CI [63], and the risk for
late relapse and second malignancies in long-term survivors of autologous transplant [22,45],
a reasonable strategy might include early autologous transplantation for otherwise healthy
high-risk patients in first or second remission. Patients who relapse later could be treated with
a RIC allogeneic transplant. At our own center, we have felt that the availability of antibody-
based and other effective therapies can often lead to clinically meaningful remissions without
including transplantation. As a result, and because of the risks of second tumors and late
relapses, we have generally preferred allogeneic to autologous transplants. We recommend
them for patients with HLA-matched donors who have less than a near complete initial
remission or remission duration of <2 years. We also limit this strategy to those patients with
good organ function, a good performance status, and chemotherapy-sensitive disease. Such an
approach may provide long-term survival for selected patients, but additional follow-up and
enrollment of both related and unrelated transplant recipients in multicenter trials such as that
from CALGB and a forthcoming BMT CTN trial will be imperative in determining the
applicability of such strategies.
LEARNING OBJECTIVES
1. Evaluate recent data regarding outcomes of autologous and allogeneic stem cell
transplant for follicular lymphoma.
2. Apply patient and disease characteristics to predict favorable post-transplant
outcomes for patients with follicular lymphoma.
3. Enumerate the indications for referral of patients with follicular lymphoma to a
transplant center.
4. Compare the advantages and disadvantages of allogeneic versus autologous stem
cell transplant for follicular lymphoma.
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